Core Viewpoint - The company, 荃信生物-B, has announced a share placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% compared to the last trading price of HKD 22.46 on August 15, 2025 [1][2] Group 1 - The placement shares will account for approximately 2.25% of the existing shares as of the announcement date and about 2.20% of the expanded share capital after the placement [1] - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - The company plans to allocate around 60% of the net proceeds to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses [2] Group 2 - Approximately 30% of the net proceeds will be used for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be allocated for working capital and other corporate purposes [2]

Group 1 - Company announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, representing approximately 2.25% of the existing shares as of the announcement date [1] - The placement price of HKD 20.0 is a discount of about 10.95% compared to the last closing price of HKD 22.46 on August 15, 2025 [1] Group 2 - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - About 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses, thereby improving the company's financial position [2] - Approximately 30% of the net proceeds will be allocated for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]

Core Viewpoint - Minxin International Holdings (08456) announced the results of its rights issue, indicating that approximately 40.8% of the total available shares were successfully subscribed, while about 59.2% remained unsubscribed [1] Group 1: Rights Issue Details - The company received valid applications for a total of 43.1581 million shares, which is about 40.8% of the total shares available for subscription under the rights issue [1] - A total of 62.6042 million shares, equivalent to approximately 59.2% of the total available shares, were not subscribed [1] - The unsubscribed shares, amounting to 62.6042 million, are subject to a placement arrangement [1] Group 2: Placement Arrangement - The placement shares, which represent about 47.4% of the company's issued shares post-rights issue, were successfully placed at a price of HKD 0.29 per share, with no premium over the subscription price [1] - The net proceeds from each unsubscribed share under the compensation arrangement amount to zero, and no action will be taken by shareholders to realize any net proceeds [1] Group 3: Financial Outcomes - The total amount raised from the rights issue is approximately HKD 30.7 million, with a net amount of about HKD 29.5 million after deducting related expenses [1] - All conditions related to the rights issue and the placement of unsubscribed shares have been fulfilled, and these shares became unconditional on August 13, 2025 [1]

Core Viewpoint - The company, Datang Xishi (00620), has announced a placement agreement to issue 66.8 million shares at a price of HKD 0.60 per share, representing approximately 8.34% of the enlarged issued share capital, aimed at raising additional funds for business development and enhancing financial stability [1] Group 1: Placement Details - The placement price of HKD 0.60 per share reflects a discount of about 3.23% compared to the closing price of HKD 0.62 on the Hong Kong Stock Exchange on August 8, 2025 [1] - The placement will involve at least six subscribers, indicating a broad interest from new investors [1] Group 2: Purpose of Fundraising - The company believes that the current market conditions present a good opportunity for further fundraising activities [1] - The funds raised will primarily support the company's property development business and supplement its working capital [1] - The placement is viewed as a cost-effective and time-efficient fundraising solution compared to debt financing, public offerings, or rights issues, as it does not impose interest burdens or affect the company's debt status [1]

Core Viewpoint - Bid International Holdings (01949) announced a conditional subscription agreement to issue 160 million subscription shares at a price of HKD 0.107 per share, representing a discount of approximately 17.69% compared to the closing price of HKD 0.130 on August 8, 2025 [1] Group 1 - The subscription shares will account for approximately 16.67% of the enlarged issued share capital after the completion of the subscription [1] - The net proceeds from the subscription, after deducting related expenses and professional fees, are expected to be around HKD 16.98 million [1] - The company plans to allocate 50% of the net proceeds for potential new business expansion into point-of-sale devices and terminal trading, and the other 50% for general working capital and administrative expenses [1] Group 2 - The board believes that the terms of the subscription agreement are fair and reasonable, and that the subscription will strengthen the company's financial position and expand its shareholder base, aligning with the overall interests of the company and its shareholders [1]

配售的募集资金净额为76.47亿港元，将按以下方式投入使用：约90%将用于加速推进全球布局和产能 建设;及约10%将用于一般公司用途。 智通财经APP讯，药明康德(02359)发布公告，董事会欣然宣布已达成所有条件并于2025年8月7日完成配 售。配售代理已根据配售协议的条款及条件按每股配售股份配售价104.27港元向不少于六名独立承配人 成功配售合共7380万股配售股份。经董事作出一切合理查询后所知、所悉及所信，承配人及其各自的最 终实益拥有人均为独立于本公司及本公司关连人士且与本公司及本公司关连人士概无关连的第三方。 ...

此次配售预计募集资金总额约7.88亿港元，净额约7.80亿港元。募集资金将主要用于研发、临床试验及 产品制造(约50%)，产品商业化(约20%)，以及补充营运资金和一般企业用途(约30%)。 博安生物宣布，已与配售代理瑞银集团订立配售协议。公司将配售总计4800万股股份，占公告日期已发 行股份总数约8.36%，配售价为每股16.42港元，较最后交易日收市价折让约8.78%。 ...

奇士达拟通过配售代理向至少六名承配人配售最多1.25亿股股份，配售价为每股0.133港元，若配售成 功，公司预计净筹约1610万港元。所得款项将主要用于偿还债务(约61.9%)及一般营运资金(约38.1%)。 ...

格隆汇8月5日丨昊天国际建投(01341.HK)公告，配售协议所载的所有条件已于2025年7月31日获达成， 而配售完成已根据配售协议的条款及条件于2025年8月5日作实。根据配售协议，公司已根据一般授权按 每股配售股份港币0.20元的配售价格向承配人配发及发行合共13亿股配售股份，相当于本公告日期公司 已发行股本（经配发及发行配售股份扩大）约14.37%。配售事项所得款项净额约为港币255.5百万元。 ...

格隆汇8月4日丨嘉鼎国际集团(08153.HK)公告，董事会欣然宣布，配售事项所有先决条件均告达成，而 配售事项已于2025年8月4日完成，并已向不少于六名承配人(均为独立第三方)配发及发行18,341,363股 新股份。配售事项所得款项净额约1.38百万港元将用作集团一般营运资金。 ...